Personalis (PSNL) News Mentions Statistics 2025

00%

1W 0% 1M 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	3 200%
	Gilead Sciences GILD	1 0%
	Catalyst Pharmaceuticals CPRX	0 100%
	Inovio Pharmaceuticals INO	0 0%
	Anavex Life Sciences AVXL	0 0%

Sumitomo Mitsui Trust Group Inc. Sells 59,295 Shares of Personalis, Inc. (NASDAQ:PSNL)

February 14

Exciting Technology At Personalis, But Profitability Eludes Them

February 13

abrdn plc Invests $1.72 Million in Personalis, Inc. (NASDAQ:PSNL)

February 11

14,980 Shares in Personalis, Inc. (NASDAQ:PSNL) Bought by China Universal Asset Management Co. Ltd.

February 4

FY2024 EPS Estimates for Personalis Decreased by Analyst

January 30

HC Wainwright Forecasts Personalis FY2029 Earnings

January 29

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

January 28

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 28

Personalis (NASDAQ:PSNL) Price Target Lowered to $8.00 at HC Wainwright

January 27

Personalis, Inc. (NASDAQ:PSNL) Shares Sold by Green Alpha Advisors LLC

January 14

Personalis’ (PSNL) Buy Rating Reiterated at HC Wainwright

January 11

Month over Month

Est. daily news mentions.

Feb 2025	0	35.4%
Jan 2025	0	9.7%
Dec 2024	0

How often is Personalis mentioned in the news?

Personalis was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Personalis performing compared to its industry peers?

Personalis underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Personalis in the last month?

There has been no significant change in the number of news mentions for Personalis' compared to the last month.

Why is it important to track news mentions for Personalis?

By monitoring mentions in the news for Personalis, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Personalis, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Personalis (PSNL) - News Mentions

Similar companies

Amgen

Gilead Sciences

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

Anavex Life Sciences

Personalis files to sell 14.04M shares of common stock for holders

Personalis sees FY25 revenue $80M-$90M, consensus $84.65M

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis (PSNL) Projected to Post Earnings on Wednesday

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference